Clinical Trials Browser

OTHER × cemiplimab × Thoracic × Clear all

NCT05401786 2026-03-12

RAD-IO

Phase 2 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT06385262 2026-03-06

TOP 2301: Neoadjuvant Chemo for NSCLC

Phase 2 Suspended

Carcinoma, Non-Small-Cell Lung

NCT07450183 2026-03-04

Perioperative Cemiplimab for Resectable Non-Small Cell Lung Cancer With High PD-L1

Phase 2 Not yet recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06918132 2026-02-24

N-PLANC

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06943664 2026-02-18

Photoimmunotherapy With ASP-1929 and Cemiplimab for the Treatment of Refractory, Inoperable, and Metastatic Stage IIIB-IV Non-small Cell Lung Cancer

Phase 2 Not yet recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT07418931 2026-02-18

CECYDE

Phase 2 Not yet recruiting

Advanced Squamous Non-Small Cell Lung Cancer

NCT06731270 2026-02-12

Diclofenac for the Treatment of Patients With Metastatic Non-small Cell Lung Cancer on Single Agent Immunotherapy

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06656598 2026-02-11

SPORADIC

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT07234058 2026-02-11

LAG-MAPS

Phase 2 Not yet recruiting

Other solid neoplasmThoracic

Mesothelioma, Malignant

NCT07360743 2026-02-10

META-1

Phase 2 Not yet recruiting

Carcinoma, Non-Small-Cell Lung

NCT05553834 2026-01-23

PCSK9 Inhibitor and PD-1 Inhibitor in Patients With Metastatic, Refractory To Prior Anti PD-1 Non-small Cell Lung

Phase 2 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT07020065 2026-01-21

Reduced-dose Carboplatin-doublet-chemotherapy + Cemiplimab vs Cemiplimab Monotherapy in Treatment Naive Older and Frail Patients With Metastatic NSCLC With PD-L1 <50%

Phase 2 Not yet recruiting

Carcinoma, Non-Small-Cell Lung

NCT07274384 2025-12-10

HYPERBOLIC

Phase 2 Not yet recruiting

Carcinoma, Non-Small-Cell Lung, Neoplasms, Disease Progression

NCT06917573 2025-11-19

PALACE

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung, Lung Diseases, Respiratory Tract Neoplasms, Thoracic Neoplasms

NCT05704634 2025-10-27

A Phase Ib Study to Evaluate the Safety and Preliminary Efficacy of IL6-receptor Antibody Sarilumab in Combination With antiPD1 Antibody Cemiplimab for Patients With Non-small Cell Lung Cancer.

Phase 1 Active not recruiting

Lung Neoplasms

NCT06623656 2025-10-23

Preoperative Radioimmunotherapy Versus Chemoimmunotherapy in NSCLC

Phase 2 Recruiting

Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasms

NCT06865339 2025-09-10

TRIPL

Phase 2 Recruiting

NSCLC

NCT07001618 2025-07-23

IMMUNOLIFE2

Phase 2 Not yet recruiting

Carcinoma, Non-Small-Cell Lung

NCT05840770 2025-05-26

Cemiplimab for the Treatment of Untreated Brain Metastases From PD-L1 >= 50% Non-Small Cell Lung Cancer

Phase 2 Withdrawn

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06743581 2024-12-20

Dupi-Cemi

Phase NA Not yet recruiting

Carcinoma, Non-Small-Cell Lung

NCT05501665 2024-10-17

Split Course Adaptive Radiation Therapy With Pembrolizumab With/Without Chemotherapy for Treating Stage IV Lung Cancer

Phase 1/2 Recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06532149 2024-08-09

EROS

Carcinoma, Non-Small-Cell Lung, Eunuchism, Erectile Dysfunction, Sexual Dysfunction, Physiological

NCT05429866 2023-03-08

Immunological Variables Associated to ICI Toxicity in Cancer Patients

Phase 2 Unknown

BreastDermatologicGastrointestinalGenitourinaryHead & NeckOther solid neoplasmThoracic

Mesothelioma, Malignant, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Gastrointestinal Neoplasms, Head and Neck Neoplasms, Carcinoma, Hepatocellular, Melanoma, Carcinoma, Merkel Cell, Small Cell Lung Carcinoma